Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

Will R Geisen; Justin Berger; Chelsea Schwartz; Abhimanyu Reddy; Balaj Rai; George Wadih; Joshua Peck

doi:10.1016/j.idcr.2020.e00962

Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

IDCases. 2020:22:e00962. doi: 10.1016/j.idcr.2020.e00962. Epub 2020 Sep 22.

Authors

Will R Geisen¹, Justin Berger¹, Chelsea Schwartz¹, Abhimanyu Reddy¹, Balaj Rai¹, George Wadih¹, Joshua Peck²

Affiliations

¹ The Christ Hospital, Department of Pathology, Cincinnati, OH, United States.
² Ohio Gastroenterology and Liver Institute, Cincinnati, OH, United States.

Abstract

The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.

Keywords: COVID-19; Colitis; Endoscopy; Immunocompromised.

Publication types

Case Reports